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Disclaimer 
The views expressed in this article are those of the author(s). 
The opinions expressed herein are those of the authors and 
do not necessarily reflect the views of the World Health 
Organization. Publication in Gates Open Research does not 
imply endorsement by the Gates Foundation.
Background
Schistosomiasis remains an endemic neglected tropical dis-
ease (NTD) affecting approximately 220 million people 
worldwide1. It is an intestinal or urogenital disease caused pre-
dominantly by Schistosoma mansoni or S. haematobium. Indi-
viduals become infected when cercariae, released by freshwater 
snails, penetrate the skin during contact with contaminated water2. 
The disease can result in anaemia, chronic pain, diarrhoea, 
and malnutrition, causing poor school performance and lower 
fitness3. Donations of the treatment drug, praziquantel, are typi-
cally offered in school-based or community-wide mass drug 
administration (MDA) programmes for schistosomiasis.
The World Health Organization (WHO) has set goals of morbid-
ity control and elimination as a public health problem (EPHP) for 
schistosomiasis to be reached by 2020 and 2025, respectively4,5 
(defined in Table 1). There are recommended WHO treat-
ment guidelines for achieving these goals based on the preva-
lence in school-aged children (SAC; aged 5–14 years old) 
prior to treatment. In low prevalence settings (≤10% SAC 
prevalence prior to treatment), MDA once every three years is 
recommended; in moderate prevalence settings (10–50% SAC 
prevalence prior to treatment), MDA once every two years is rec-
ommended; and in high prevalence settings (≥50% SAC preva-
lence prior to treatment), annual MDA is recommended4,5. MDA 
coverage has mainly focused on reaching 75% of SAC with treat-
ment of adults at risk also recommended4,5. The WHO end goal 
for schistosomiasis is interruption of transmission (IOT) which 
is achieved once the incidence of infection is reduced to zero4,5. 
In May 2019, following a Global Schistosomiasis Alliance con-
sultation meeting with its members and the WHO, there was 
support for the IOT goal with an interim and complementary 
goal of reducing the burden of schistosomiasis6.
Mathematical models of transmission dynamics and the 
impact of control interventions have been developed to inform 
decision makers on the optimal treatment strategies which are 
required for achieving the WHO goals. The Gates-funded NTD 
Modelling Consortium brings together multiple institutional 
groups working on NTDs, including schistosomiasis. Modelling 
groups based at Imperial College London (ICL) and Case Western 
Reserve University (CWRU), along with other collaborators 
have led the recent work for schistosomiasis. A model 
comparison was carried out for the ICL and CWRU models, 
and a joint policy paper was also produced7,8. Due to knowledge 
gaps surrounding the epidemiology of schistosomiasis, the 
models have contrasting underlying assumptions leading to 
differences in model predictions8. Despite these differences, the 
models generally agree on the treatment strategies required to 
achieve EPHP for S. mansoni, thereby strengthening the evidence 
for our model recommendations7.
Moving towards the post-2020 goals, new WHO goals have 
been proposed for the NTDs to be reached by 2030. Currently, 
the proposed 2030 goal for schistosomiasis is EPHP. Using 
the insights that have been gained from recent modelling work 
on S. mansoni, we highlight the practical implications of EPHP 
(the timelines and feasibility of achieving EPHP) and the risks 
Table 1. Summary of modelling insights and challenges for reaching the WHO 2030 goal for Schistosoma mansoni.
Current WHO Goal (2020 Goal) Morbidity control: <5% prevalence of heavy-intensity infections (eggs per gram ≥400) in school-aged children (SAC; 5–14 years old).
Proposed New WHO Goal (2030 
Goal)
Elimination as a public health problem (EPHP): <1% prevalence of heavy-intensity infections 
in SAC. Note that this is the current 2025 goal.
Is the new goal technically 
feasible under the current 
disease strategy?
In low to moderate prevalence settings (<50% SAC prevalence prior to treatment), EPHP is 
likely to be achieved with 75% SAC-only treatment.
If not, what is required to achieve 
the goal? 
As prevalence rises in high prevalence settings (≥50% SAC prevalence prior to treatment), 
EPHP becomes infeasible unless the disease strategy is scaled-up to treat both SAC and 
adults. Required coverage levels increase with the adult burden of infection.
Are current tools able to reliably 
measure the goal?
No; as Kato-Katz has low sensitivity at low prevalence levels, more sensitive diagnostics 
(able to measure prevalence and intensity of infection) will allow for smaller sample sizes 
and/or higher prevalence thresholds when measuring the goal. 
What are the biggest unknowns?
Prevalence levels and intensity of infections across all age groups (i.e. full age profile 
of infection); levels of systematic non-adherence and ideal size of implementation unit; 
modelling insights on S. haematobium and other species. 
What are the biggest risks?
Stopping treatment after achieving EPHP is highly likely to lead to resurgence of infection. 
Interruption of transmission (IOT) would alleviate the need for ongoing treatment. 
Potential risks posed by zoonotic reservoirs and drug resistance.
      Amendments from Version 1
Following helpful reviewer comments, we have revised our letter 
to improve the clarity of our insights. Specific points added are 
as follows: uncertainty around how reliable the current WHO 
definition of EPHP is for estimating a reduction in schistosomiasis-
related morbidity; our modelling assumptions on treatment 
coverage and adherence; input from the Global Schistosomiasis 
Alliance meeting to show views of its members. More references 
have also been added where needed.
Any further responses from the reviewers can be found at the 
end of the article
REVISED
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that need to be mitigated to maintain this goal. There is uncer-
tainty around how reliable the current WHO definition of EPHP 
is for estimating a reduction in schistosomiasis-related morbid-
ity as lower intensity infections may also be associated with 
significant morbidity3. Further modelling will be required fol-
lowing revision of this goal by WHO as this may impact 
our recommended treatment strategies.
Note that the following sections focus on S. mansoni and 
Kato-Katz (as this is the currently recommended diagnostic 
technique9). Additionally, the current WHO treatment guide-
lines and EPHP goal have been investigated here but these are 
currently under revision by WHO. Importantly, our modelling 
insights remain relevant as we highlight where the current 
guidelines are sufficient and where programmatic adaptations 
are needed for achieving the current EPHP goal (refer to Table 1 
for a summary).
Insights gained from quantitative and mathematical 
modelling analyses
Using models developed independently by ICL and CWRU, we 
investigated whether the currently recommended WHO guidelines 
(of 75% SAC-only treatment) are sufficient for achieving 
the EPHP goal for S. mansoni. Our modelling and data analyses 
showed that these guidelines are sufficient for reaching EPHP 
in low to moderate settings7,10. However, as prevalence rises 
within high settings, an increase and expansion in treatment 
coverage to include adults, as well as SAC, is required to 
reach EPHP with coverage levels dependent on the setting7,10 
(Table 2). As the burden of infection (intensity of transmis-
sion) in adults relative to SAC increases, the coverage levels 
needed to achieve EPHP increase (Figure 1)10. Coverage levels 
also increase if EPHP is to be achieved within a shorter amount 
of time (Figure 1).
Monitoring and evaluation (M&E) programmes are used to col-
lect data to assess the progress of a treatment programme and 
to determine the appropriate treatment strategy. M&E data 
are typically collected from SAC as they are relatively easy to 
sample from. However, as the optimal treatment strategy for 
S. mansoni depends on the burden of infection in SAC and 
adults, M&E prevalence and infection intensity data need to be 
collected from a broader age-range10. Our work has also shown 
that despite achieving EPHP, the prevalence may still be high 
Table 2. Model recommended treatment strategies for achieving elimination as a public health problem (EPHP) in low 
to high prevalence settings. SAC refers to school-aged children aged 5–14 years old.
Prevalence in SAC 
prior to treatment
Model recommended treatment strategy for achieving EPHP
Low (<10%) 75% SAC treatment once every 3 years within 6 years7.
Moderate (10%–50%) 75% SAC treatment once every 2 years for up to 5 years (this holds for low to high adult burdens of infection)10. 
High (≥50%)
As prevalence rises, SAC and adult annual treatment with coverage levels increasing with the adult 
burden of infection (coverage also increases as programme duration shortens; shown for 5–10 year 
programmes in Figure 1)10.
Figure 1. Coverage levels required to reach the WHO goal of elimination as a public health problem (EPHP) in a high prevalence 
setting (≥50% SAC baseline prevalence) within 5- and 10-year annual treatment programmes (assuming random coverage and no 
non-adherence). School-aged children (SAC) are 5–14 years old and adults are 15+ years old. This figure has been reproduced from 10 
under a Creative Commons Attribution 4.0 International (CC BY 4.0) license.
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due to light- to moderate-intensity infections persisting in 
SAC, in addition to all the infections remaining in pre-SAC 
and adults7,10. Therefore, stopping treatment after reaching EPHP 
poses a high risk of resurgence.
Practical implications of the elimination as a public 
health problem goal
Timelines and feasibility of achieving elimination as a 
public health problem
The treatment strategy required to achieve EPHP is determined 
by the epidemiological and ecological setting, such as the base-
line prevalence/transmission intensity7,10. EPHP is technically 
feasible in all settings within 10 years provided that the appro-
priate treatment strategy is used. Table 2 shows the model 
recommended treatment strategies. Achieving and maintain-
ing high coverage, adherence and treatment opportunities over 
each round of treatment is essential11. Here, we have assumed 
treatment at random with full adherence at each round of MDA. 
Areas with poor school enrolment may benefit more from 
community-wide treatment12.
Measuring the elimination as a public health problem goal
To monitor and assess progress towards the EPHP goal, preva-
lence and infection intensity data are required from SAC (as the 
goal is defined by <1% prevalence of heavy-intensity infec-
tions in SAC). The goal is typically assessed by averaging the 
prevalence measured in five schools randomly sampled within 
a district13. This approach does not take into account the high 
spatial heterogeneity and focality in Schistosoma prevalence. 
Taking implementation decisions at the district level using 
the currently proposed sampling strategy can lead to under- 
and over-treatment of SAC. Sampling fewer children in more 
schools has been shown to improve prevalence estimates, reduc-
ing under-treatment13. Ongoing work on mapping protocols will 
allow for more precise targeted treatment.
Kato-Katz is currently the recommended diagnostic test, but 
there are relatively newer, more sensitive diagnostics avail-
able. Due to the reduced sensitivity of diagnostic techniques at 
low prevalence levels, the true prevalence is likely to be higher 
than the measured prevalence. Prevalence measured with Kato-
Katz will be lower relative to that measured with more sensitive 
diagnostics, such as point-of-care circulating cathodic antigen 
(POC-CCA) tests, and this difference has been analysed, 
although the relationship between the two diagnostics remains 
unclear14–16. Therefore, the diagnostic technique used will 
impact the sampling strategy, with a more sensitive diagnos-
tic likely facilitating the sampling of fewer people or the use of 
higher prevalence thresholds when measuring EPHP and 
furthermore IOT17.
Considerations of cost
Accurate, representative data on which age groups are infected 
are required to determine the most cost-effective treatment 
strategy, for example, only collecting data on high-risk adults 
can overestimate the benefit of community-wide treatment12. 
The costs of diagnostic techniques also need to be considered. 
Although the traditional Kato-Katz diagnostic is seen as the 
cheaper test, given the increased sensitivity of POC-CCA, this 
may outweigh costs in the long term18.
Risks faced by treatment programmes
There are risks that need to be mitigated to achieve EPHP. Indi-
viduals with no access to treatment or those not taking treatment 
in any round of MDA (systematic non-adherers) may result in 
maintained transmission11,19. Due to systematic non-adherence, 
reported coverage may be higher than true coverage19. Ideally 
data on adherence as well as coverage should be collected within 
M&E programmes as both will impact the outcome of treatment 
programmes19.
M&E programmes focus on SAC, and may be biased to those 
who are treated, making it difficult to promptly identify a fail-
ing treatment programme. Therefore, it is vital that the M&E 
data collected is representative of each age group10,12. Manipula-
tion of implementation unit size may mask persistent prevalence 
of challenging locations, such as hotspots. Guidance on mapping 
of schistosomiasis prevalence will aid in determining the opti-
mal size of implementation units. Further risks which may 
reduce the effectiveness of treatment programmes are poten-
tial drug resistance (declining praziquantel efficacy following 
multiple rounds of treatment20) and the presence of zoonotic 
reservoirs21,22. More insights are needed on such risks as 
more intensified treatment strategies than those currently 
recommended here may be required if they are present.
Following achievement of EPHP, infections may remain 
present in the population resulting in resurgence if treatment is 
stopped7,10. Pre-SAC can also be infected with schistosomes 
and a reservoir of infection may remain in this age group fol-
lowing MDA to other age groups. Development of a paediatric 
formulation of praziquantel for pre-SAC treatment would pre-
vent this23. Due to remaining infections, it is highly likely that 
treatment will still be needed to maintain control after achiev-
ing EPHP24. Good water, sanitation and hygiene could aid 
in sustaining EPHP, allowing treatment to be scaled down25.
Moving towards interruption of transmission
To alleviate the need for ongoing treatment and to prevent resur-
gence, IOT is required after reaching EPHP2,7,10. The transition of 
treatment programmes from EPHP to IOT will require reassess-
ment of the treatment strategy, with consideration of complemen-
tary interventions such as behaviour change and snail control. Once 
very low prevalence levels have been achieved and a treatment 
programme is stopped, surveillance is needed to ensure that IOT 
has been achieved and that resurgence has not occurred. Currently, 
there is little guidance available for programmes when stop-
ping treatment. Recently, the ICL model determined the post- 
treatment surveillance criteria for predicting IOT for S. mansoni. 
Results showed that a 1% Kato-Katz prevalence measured 
2 years (or later) after stopping treatment across 200 individu-
als (randomly sampled from all age groups in a population of 
500–1000 individuals), means IOT is 90% likely in the absence 
of re-introduction17.
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detailed in background section; Table 1.1 recommended treatment strategy for schistosomiasis in
WHO reference 4 of paper which is for morbidity control and EPHP). WHO reference 4a has also
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** We are presenting these results as modelling insights and are aware of the risks faced by
treatment programmes which will mean that our model recommendations are too optimistic if such
risks are faced.
We have clarified the model assumptions on coverage and adherence in the timelines section:
“Here, we have assumed treatment at random with full adherence at each round of MDA”. We have
added “More insights are needed on such risks as more intensified treatment strategies than those
currently recommended here may be required if they are present” to the risks faced by treatment
programmes section (also within our biggest unknowns and risks in Table 1). 
















^ The following has been added to the background: “In May 2019, following a Global
Schistosomiasis Alliance consultation meeting with its members and the WHO, there was support
for the IOT goal with an interim and complementary goal of reducing the burden of schistosomiasis







This is explained in the background section: “MDA coverage has mainly focused on reaching 75%
of SAC with treatment of adults at risk also recommended.” We are using the WHO recommended
treatment strategy shown in Table 1.1 and 2.2 in reference 4 and 4a of paper, respectively. This
refers to treatment of SAC and adults at risk. To maintain clarity of which WHO guidelines we have






Control measures investigated vary within the consortium. ICL looks at MDA, whereas, CWRU
4b
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Control measures investigated vary within the consortium. ICL looks at MDA, whereas, CWRU
looks at MDA and snail control. We look at both prevalence and intensity. We feel this is too
detailed to add to the abstract and have made it clear throughout the letter that we are focussing on










Using current WHO guidelines as stated. We use WHO definitions for low, moderate and high
prevalence settings which are explained in the background section and tables 1-2.
5. The authors write: “However, as prevalence rises within higher settings…”. The authors might
consider defining “higher setting”. The sentence needs revision.
Edited to “as prevalence rises within high prevalence settings…” Using WHO definition for high




This is explained in the insights gained from quantitative and mathematical modelling analyses




IOT has been mentioned in the background: “The WHO end goal for schistosomiasis is interruption
of transmission (IOT) which is achieved once the incidence of infection is reduced to zero .”
8. “EPHP” should be defined at the beginning so that the reader better understands the following
sentence “Additionally, even though EPHP may be reached, prevalence can still be high”.




Treatment has been left broad here as it does not mean only MDA necessarily, e.g. could include
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This has been mentioned in the background: “The WHO end goal for schistosomiasis is
















The last paragraph of the background section has been edited to make clearer that we have
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See response to comment 2 in abstract and *.
8. The authors write: “As the burden of infection in adults relative to SAC increases…”. The authors
might define burden. Is it measured in intensity, worm numbers, DALYs or something else?
The burden relates to the transmission intensity - The age-specific contact rates, i.e. transmission
intensities by age group, were varied such that the adults have a low or high burden of infection
relative to SAC. This has been clarified in the sentence referred to: “As the burden of infection












Agree, we are planning to do this. Our modelling insights here are assuming 100% adherence and








*** We are referring to the current EPHP goal here as stated at the end of the background section.
Defined in table 4.4 in reference 4a (reference has been added to letter) as heavy-intensity





5 schools per district are frequently surveyed for mapping schistosomiasis. This has been edited
to: “The goal is currently typically assessed by averaging the prevalence measured in five schools










Page 22 of 25






We have not used our modelling analyses to determine the coverage at which paediatric
















We are referring to MDA and broader intervention strategies. The following has been added to the














We agree and this is part of our ongoing work. However, the priority questions listed here are those
 which have been identified in discussions with WHO.
 No competing interests were disclosed.Competing Interests:
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